Loading summary...
- Home
- report store
- vernal keratoconjunctivitis market insight
Vernal Keratoconjunctivitis - Market Insight, Epidemiology and Market Forecast -2034
Published Date : 2025
Pages : 200
Region : United States, Japan, EU4 & UK
- Summary
- Sample Request
1 Key Insights
2 Report Introduction
3 VKC Market Overview at a Glance
3.1. Market Share (%) Distribution of VKC in 2020
3.2. Market Share (%) Distribution of VKC by 2034
4 Epidemiology and Market Methodology
5 Executive Summary
6 VKC Key Events
7 Disease Background and Overview: VKC
7.1. Introduction
7.2 Causes
7.3 Pathophysiology
7.4 Symptoms
7.5 Risk Factor
7.6. Diagnosis
7.6.1. Diagnostic Algorithm
7.6.2. Diagnostic Guidelines
7.7 Treatment and Management of VKC
7.7.1 Treatment Algorithm
7.7.2 Treatment Guidelines
8 Epidemiology and Patient Population
8.1. Key Findings
8.2 Assumptions and Rationale: The 7MM
8.3 Total Prevalent Cases of VKC in the 7MM
8.4 Total Diagnosed Prevalent Cases of VKC in the 7MM
8.5. The US
8.5.1 Total Prevalent Cases of VKC
8.5.2 Total Diagnosed Prevalent Cases of VKC
8.5.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.5.4 Type-specific Diagnosed Prevalent Cases of VKC
8.5.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.5.6 Age-specific Diagnosed Prevalent Cases of VKC
8.6. EU4 and the UK
8.6.1. Germany
8.6.1.1 Total Prevalent Cases of VKC
8.6.1.2 Total Diagnosed Prevalent Cases of VKC
8.6.1.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.6.1.4 Type-specific Diagnosed Prevalent Cases of VKC
8.6.1.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.6.1.6 Age-specific Diagnosed Prevalent Cases of VKC
8.6.2. France
8.6.2.1 Total Prevalent Cases of VKC
8.6.2.2 Total Diagnosed Prevalent Cases of VKC
8.6.2.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.6.2.4 Type-specific Diagnosed Prevalent Cases of VKC
8.6.2.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.6.2.6 Age-specific Diagnosed Prevalent Cases of VKC
8.6.3. Italy
8.6.3.1 Total Prevalent Cases of VKC
8.6.3.2 Total Diagnosed Prevalent Cases of VKC
8.6.3.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.6.3.4 Type-specific Diagnosed Prevalent Cases of VKC
8.6.3.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.6.3.6 Age-specific Diagnosed Prevalent Cases of VKC
8.6.4. Spain
8.6.4.1 Total Prevalent Cases of VKC
8.6.4.2 Total Diagnosed Prevalent Cases of VKC
8.6.4.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.6.4.4 Type-specific Diagnosed Prevalent Cases of VKC
8.6.4.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.6.4.6 Age-specific Diagnosed Prevalent Cases of VKC
8.6.5. The UK
8.6.5.1 Total Prevalent Cases of VKC
8.6.5.2 Total Diagnosed Prevalent Cases of VKC
8.6.5.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.6.5.4 Type-specific Diagnosed Prevalent Cases of VKC
8.6.5.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.6.5.6 Age-specific Diagnosed Prevalent Cases of VKC
8.7. Japan
8.7.1 Total Prevalent Cases of VKC
8.7.2 Total Diagnosed Prevalent Cases of VKC
8.7.3 Gender-specific Diagnosed Prevalent Cases of VKC
8.7.4 Type-specific Diagnosed Prevalent Cases of VKC
8.7.5 Severity-specific Diagnosed Prevalent Cases of VKC
8.7.6 Age-specific Diagnosed Prevalent Cases of VKC
9 Patient Journey
10 Marketed Therapies
10.1 Key Cross Competition
10.2 VERKAZIA (Cyclosporine Ophthalmic Emulsion): Santen Pharmaceutical
10.2.1 Product Description
10.2.2 Other Development Activities
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
The list will be continued in the report
11 VKC: Seven Major Market Analysis
11.1 Key Findings
11.2 Market Outlook
11.3 Key Market Forecast Assumptions
11.4 Total Market Size of VKC in the 7MM
11.5 Market Size of VKC by Therapies in the 7MM
11.6 Conjoint Analysis
11.7 The United States Market Size
11.7.1 Total Market Size of VKC
11.7.2 Market Size of VKC by Therapies
11.8 Market Size of VKC in the EU4 and the UK
11.8.1. Germany
11.8.1.1 Total Market Size of VKC
11.8.1.2 Market Size of VKC by Therapies
11.8.2. France
11.8.2.1. Total Market Size of VKC
11.8.2.2. Market Size of VKC by Therapies
11.8.3. Italy
11.8.3.1. Total Market Size of VKC
11.8.3.2. Market Size of VKC by Therapies
11.8.4. Spain
11.8.4.1. Total Market Size of VKC
11.8.4.2. Market Size of VKC by Therapies
11.8.5. The United Kingdom
11.8.5.1. Total Market Size of VKC
11.8.5.2. Market Size of VKC by Therapies
11.9. Japan Market Size
11.9.1 Total Market Size of VKC
11.9.2 Market Size of VKC by Therapies
12 Key Opinion Leaders’ Views
13 Unmet Needs
14 SWOT Analysis
15 VKC Market Access and Reimbursement
16 Appendix
16.2 Bibliography
16.2 Abbreviations and Acronyms
16.3 Report Methodology
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
List of Tables:
Table 1 Total Prevalent Cases of VKC in the 7MM (2020–2034)
Table 2 Total Diagnosed Prevalent Cases of VKC in the 7MM (2020–2034)
Table 3 Total Prevalent Cases of VKC in the US
Table 4 Total Diagnosed Prevalent Cases of VKC in the US
Table 5 Gender-specific Diagnosed Prevalent Cases of VKC in the US
Table 6 Type-specific Diagnosed Prevalent Cases of VKC in the US
Table 7 Severity-specific Diagnosed Prevalent Cases of VKC in the US
Table 8 Age-specific Diagnosed Prevalent Cases of VKC in the US
Table 9 Total Prevalent Cases of VKC in Germany
Table 10 Total Diagnosed Prevalent Cases of VKC in Germany
Table 11 Gender-specific Diagnosed Prevalent Cases of VKC in Germany
Table 12 Type-specific Diagnosed Prevalent Cases of VKC in Germany
Table 13 Severity-specific Diagnosed Prevalent Cases of VKC in Germany
Table 14 Age-specific Diagnosed Prevalent Cases of VKC in Germany
Table 15 Total Prevalent Cases of VKC in France
Table 16 Total Diagnosed Prevalent Cases of VKC in France
Table 17 Gender-specific Diagnosed Prevalent Cases of VKC in France
Table 18 Type-specific Diagnosed Prevalent Cases of VKC in France
Table 19 Severity-specific Diagnosed Prevalent Cases of VKC in France
Table 20 Age-specific Diagnosed Prevalent Cases of VKC in France
Table 21 Total Prevalent Cases of VKC in Italy
Table 22 Total Diagnosed Prevalent Cases of VKC in Italy
Table 23 Gender-specific Diagnosed Prevalent Cases of VKC in Italy
Table 24 Type-specific Diagnosed Prevalent Cases of VKC in Italy
Table 25 Severity-specific Diagnosed Prevalent Cases of VKC in Italy
Table 26 Age-specific Diagnosed Prevalent Cases of VKC in Italy
Table 27 Total Prevalent Cases of VKC in Spain
Table 28 Total Diagnosed Prevalent Cases of VKC in Spain
Table 29 Gender-specific Diagnosed Prevalent Cases of VKC in Spain
Table 30 Type-specific Diagnosed Prevalent Cases of VKC in Spain
Table 31 Severity-specific Diagnosed Prevalent Cases of VKC in Spain
Table 32 Age-specific Diagnosed Prevalent Cases of VKC in Spain
Table 33 Total Prevalent Cases of VKC in the UK
Table 34 Total Diagnosed Prevalent Cases of VKC in the UK
Table 35 Gender-specific Diagnosed Prevalent Cases of VKC in the UK
Table 36 Type-specific Diagnosed Prevalent Cases of VKC in the UK
Table 37 Severity-specific Diagnosed Prevalent Cases of VKC in the UK
Table 38 Age-specific Diagnosed Prevalent Cases of VKC in the UK
Table 39 Total Prevalent Cases of VKC in Japan
Table 40 Total Diagnosed Prevalent Cases of VKC in Japan
Table 41 Gender-specific Diagnosed Prevalent Cases of VKC in Japan
Table 42 Type-specific Diagnosed Prevalent Cases of VKC in Japan
Table 43 Severity-specific Diagnosed Prevalent Cases of VKC in Japan
Table 44 Age-specific Diagnosed Prevalent Cases of VKC in Japan
Table 45 VERKAZIA (Cyclosporine Ophthalmic Emulsion), Clinical Trial Description, 2024
Table 46 Total Market Size of VKC in the 7MM (2020–2034)
Table 47 VKC Market Size by Therapies in the 7MM (2020–2034)
Table 48 Total Market Size of VKC in the United States (2020–2034)
Table 49 VKC Market Size by Therapies in the United States (2020–2034)
Table 50 Total Market Size of VKC in Germany (2020–2034)
Table 51 VKC Market Size by Therapies in Germany (2020–2034)
Table 52 Total Market Size of VKC in France (2020–2034)
Table 53 VKC Market Size by Therapies in France (2020–2034)
Table 54 Total Market Size of VKC in Italy (2020–2034)
Table 55 VKC Market Size by Therapies in Italy (2020–2034)
Table 56 Total Market Size of VKC in Spain (2020–2034)
Table 57 VKC Market Size by Therapies in Spain (2020–2034)
Table 58 Total Market Size of VKC in the UK (2020–2034)
Table 59 VKC Market Size by Therapies in the UK (2020–2034)
Table 60 Total Market Size of VKC in EU4 and the UK (2020–2034)
Table 61 VKC Market Size by Therapies in EU4 and the UK (2020–2034)
Table 62 Total Market Size of VKC in Japan (2020–2034)
Table 63 VKC Market Size by Therapies in Japan (2020–2034)
List of Figures:
Figure 1 Total Prevalent Cases of VKC in the 7MM (2020–2034)
Figure 2 Total Diagnosed Prevalent Cases of VKC in the 7MM (2020–2034)
Figure 3 Total Prevalent Cases of VKC in the US
Figure 4 Total Diagnosed Prevalent Cases of VKC in the US
Figure 5 Gender-specific Diagnosed Prevalent Cases of VKC in the US
Figure 6 Type-specific Diagnosed Prevalent Cases of VKC in the US
Figure 7 Severity-specific Diagnosed Prevalent Cases of VKC in the US
Figure 8 Age-specific Diagnosed Prevalent Cases of VKC in the US
Figure 9 Total Prevalent Cases of VKC in Germany
Figure 10 Total Diagnosed Prevalent Cases of VKC in Germany
Figure 11 Gender-specific Diagnosed Prevalent Cases of VKC in Germany
Figure 12 Type-specific Diagnosed Prevalent Cases of VKC in Germany
Figure 13 Severity-specific Diagnosed Prevalent Cases of VKC in Germany
Figure 14 Age-specific Diagnosed Prevalent Cases of VKC in Germany
Figure 15 Total Prevalent Cases of VKC in France
Figure 16 Total Diagnosed Prevalent Cases of VKC in France
Figure 17 Gender-specific Diagnosed Prevalent Cases of VKC in France
Figure 18 Type-specific Diagnosed Prevalent Cases of VKC in France
Figure 19 Severity-specific Diagnosed Prevalent Cases of VKC in France
Figure 20 Age-specific Diagnosed Prevalent Cases of VKC in France
Figure 21 Total Prevalent Cases of VKC in Italy
Figure 22 Total Diagnosed Prevalent Cases of VKC in Italy
Figure 23 Gender-specific Diagnosed Prevalent Cases of VKC in Italy
Figure 24 Type-specific Diagnosed Prevalent Cases of VKC in Italy
Figure 25 Severity-specific Diagnosed Prevalent Cases of VKC in Italy
Figure 26 Age-specific Diagnosed Prevalent Cases of VKC in Italy
Figure 27 Total Prevalent Cases of VKC in Spain
Figure 28 Total Diagnosed Prevalent Cases of VKC in Spain
Figure 29 Gender-specific Diagnosed Prevalent Cases of VKC in Spain
Figure 30 Type-specific Diagnosed Prevalent Cases of VKC in Spain
Figure 31 Severity-specific Diagnosed Prevalent Cases of VKC in Spain
Figure 32 Age-specific Diagnosed Prevalent Cases of VKC in Spain
Figure 33 Total Prevalent Cases of VKC in the UK
Figure 34 Total Diagnosed Prevalent Cases of VKC in the UK
Figure 35 Gender-specific Diagnosed Prevalent Cases of VKC in the UK
Figure 36 Type-specific Diagnosed Prevalent Cases of VKC in the UK
Figure 37 Severity-specific Diagnosed Prevalent Cases of VKC in the UK
Figure 38 Age-specific Diagnosed Prevalent Cases of VKC in the UK
Figure 39 Total Prevalent Cases of VKC in Japan
Figure 40 Total Diagnosed Prevalent Cases of VKC in Japan
Figure 41 Gender-specific Diagnosed Prevalent Cases of VKC in Japan
Figure 42 Type-specific Diagnosed Prevalent Cases of VKC in Japan
Figure 43 Severity-specific Diagnosed Prevalent Cases of VKC in Japan
Figure 44 Age-specific Diagnosed Prevalent Cases of VKC in Japan
Figure 45 Patient Journey
Figure 46 Total Market Size of VKC in the 7MM (2020–2034)
Figure 47 VKC Market Size by Therapies in the 7MM (2020–2034)
Figure 48 Total Market Size of VKC in the United States (2020–2034)
Figure 49 VKC Market Size by Therapies in the United States (2020–2034)
Figure 50 Total Market Size of VKC in Germany (2020–2034)
Figure 51 VKC Market Size by Therapies in Germany (2020–2034)
Figure 52 Total Market Size of VKC in France (2020–2034)
Figure 53 VKC Market Size by Therapies in France (2020–2034)
Figure 54 Total Market Size of VKC in Italy (2020–2034)
Figure 55 VKC Market Size by Therapies in Italy (2020–2034)
Figure 56 Total Market Size of VKC in Spain (2020–2034)
Figure 57 VKC Market Size by Therapies in Spain (2020–2034)
Figure 58 Total Market Size of VKC in the UK (2020–2034)
Figure 59 VKC Market Size by Therapies in the UK (2020–2034)
Figure 60 Total Market Size of VKC in EU4 and the UK (2020–2034)
Figure 61 VKC Market Size by Therapies in EU4 and the UK (2020–2034)
Figure 62 Total Market Size of VKC in Japan (2020–2034)
Figure 63 VKC Market Size by Therapies in Japan (2020–2034)
Figure 64 SWOT Analysis
Figure 65 Unmet Needs
License Type
Offer
Vernal Keratoconjunctivitis Market Summary
Get a Sneak Peek at the Latest vernal keratoconjunctivitis market insight Report
Request Sample
View Pricing
Customize Reports As Per Your Needs
Don't see what you're looking for? Get a report tailored to your specific requirements. Customize your report now!
DelveInsight
SUBSCRIPTION
Platform
SUBSCRIPTION
Platform
Register for free trial today and gain instant access to 7000+ market
research reports